Magnetic resonance imaging in patients with cardiac pacemakers: era of "MR Conditional" designs by Shinbane, Jerold S et al.
REVIEW Open Access
Magnetic resonance imaging in patients with
cardiac pacemakers: era of “MR Conditional”
designs
Jerold S Shinbane
1*, Patrick M Colletti
2 and Frank G Shellock
2
Abstract
Advances in cardiac device technology have led to the first generation of magnetic resonance imaging (MRI)
conditional devices, providing more diagnostic imaging options for patients with these devices, but also new
controversies. Prior studies of pacemakers in patients undergoing MRI procedures have provided groundwork for
design improvements. Factors related to magnetic field interactions and transfer of electromagnetic energy led to
specific design changes. Ferromagnetic content was minimized. Reed switches were modified. Leads were
redesigned to reduce induced currents/heating. Circuitry filters and shielding were implemented to impede or limit
the transfer of certain unwanted electromagnetic effects. Prospective multicenter clinical trials to assess the safety
and efficacy of the first generation of MR conditional cardiac pacemakers demonstrated no significant alterations in
pacing parameters compared to controls. There were no reported complications through the one month visit
including no arrhythmias, electrical reset, inhibition of generator output, or adverse sensations. The safe
implementation of these new technologies requires an understanding of the well-defined patient and MR system
conditions. Although scanning a patient with an MR conditional device following the strictly defined patient and
MR system conditions appears straightforward, issues related to patients with pre-existing devices remain complex.
Until MR conditional devices are the routine platform for all of these devices, there will still be challenging
decisions regarding imaging patients with pre-existing devices where MRI is required to diagnose and manage a
potentially life threatening or serious scenario. A range of other devices including ICDs, biventricular devices, and
implantable physiologic monitors as well as guidance of medical procedures using MRI technology will require
further biomedical device design changes and testing. The development and implementation of cardiac MR
conditional devices will continue to require the expertise and collaboration of multiple disciplines and will need to
prove safety, effectiveness, and cost effectiveness in patient care.
Introduction
In a previous JCMR paper entitled, “MRI in Patients
with Pacemakers and ICDs: Defining the Issues”,t h e
authors discussed controversies related to imaging
patients with cardiac pacemakers and implantable car-
diac defibrillators (ICDs) which had not been specifically
designed for the magnetic resonance imaging (MRI)
environment [1]. Since that time, technological advances
have led to the first generation of MR conditional car-
diac pacemakers, allowing for greater patient
management options as well as a new set of issues and
controversies. One paradoxical effect created by this
burst of medical innovation is the potential limitation of
application of a technology due to the presence of
another technology in the same patient. Because a sig-
nificant percentage of patients with cardiac devices may
potentially have indications for MRI during their lifetime
[2], application of MR conditional devices is important
to allowing patients access to MR scanning under well
defined conditions. The engineering and implementation
of these devices requires an understanding of: 1) all
device/MRI interactions, 2) design issues to minimize or
eliminate these interactions, and 3) patient management
decision-making algorithms for their safe application.
This review will discuss the development and
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and issues related to future design and implementation
of other cardiac devices.
Studies of MRI/Cardiac Pacemaker Interactions
Previous studies have identified issues laying the
groundwork for design improvements to engineer so-
called MR conditional devices with the MRI environ-
ment under strict conditions for the patient, the device,
and MRI parameters. The term, “MR conditional” refers
to an item that has been demonstrated to pose no
known hazards in a specified MR environment with spe-
cified conditions of use [3]. “Field” conditions that
define the MR environment include static magnetic field
strength, spatial gradient magnetic field, dB/dt (time
rate of change of the magnetic field), radio frequency
(RF) fields, and specific absorption rate (SAR). Addi-
tional conditions, including specific configurations of
the item (e.g., the routing of leads used for a neurosti-
mulation system), may be required.
The medical literature from the pre-MR conditional
cardiac device era arises from: 1) in vitro investigations
of cardiac pacemakers and implantable cardiac defibril-
lators (ICDs), 2) isolated case reports, 3) retrospective
series of patients with devices unintentionally or inten-
tionally placed in the MRI environment and 4) prospec-
tive studies with defined patient and MR conditions
[4-69]. Additionally, a physician initiated prospective
multicenter site registry of pacemakers and ICDs using
1.5 Tesla non-thoracic scans has been initiated (The
MagnaSafe Registry) [70,71]. Table 1 summarizes in vivo
human data related to both pacemakers and ICDs.
These data demonstrated certain adverse interactions of
cardiac pacemakers and ICDs in the MRI environment
and provided variable results regarding safety with pro-
spective studies under defined conditions. These data
led to controversy regarding study under well-defined
conditions in cases where the use of MRI was essential
to patient management versus the need for devices engi-
neered to be MR conditional [1,72-79]. The issues raised
by these data, however, were essential to prospective
multicenter human studies completed [80-82], ongoing
[83], and planned [84] to assess the safety and efficacy
of the first generation of MR conditional cardiac
pacemakers.
In a randomized, unblinded, two arm study of patients
who met standard criteria for dual chamber pacing (484
enrolled, 464 with successful implant, 258 randomized
to a single non-medically indicated MRI scan and 206
randomized to a control group) there were no signifi-
cant changes in pacing parameters (sensing, threshold,
or impedance change) compared to controls [81]. Both
pacemaker-dependent and non-pacemaker dependent
patients were studied, with MR scanning in the
asynchronous mode (n = 158), and no pacing (n = 67)
with a continuous stable rhythm during scanning.
Although pacemaker dependence was not assessed at
the time of scanning, 16 MR scanned and 11 control
patients had no underlying intrinsic ventricular rhythm
at the pre-9- to 12-week assessment. There were no
reported complications through the one month visit
including arrhythmias, electrical reset, inhibition of gen-
erator output, or adverse sensations.
The safe implementation of new MR conditional tech-
nologies requires a detailed understanding of the MR
nomenclature as it relates to specific patient and scan-
ning conditions [3]. The American Society of Testing
M a t e r i a l s( A S T M )d e s i g n a t e sd e v i c e sa sM Rs a f e ,M R
conditional, and MR unsafe [85]. As an MR safe device
would require nonmetallic, non-conducting materials
and systems with no known hazards in all MR environ-
ments, it would be impossible to develop a pacing sys-
tem with this designation. As MR conditional refers to
devices which pose no known hazards when applied
with specific conditions and a specific MR environment,
the approval of a device requires strict definition of
these conditions. Recently, the United States Food and
Drug Administration (FDA) approved an MR condi-
tional pacing system, the Revo™ MRI SureScan
® Pacing
System (Medtronic, Inc., Minneapolis, MN) [81]. Out-
side of the United States [Biotronik (Berlin, Germany),
Medtronic, Inc. (Minneapolis, MN), and St. Jude Medi-
cal (St. Paul, MN), there are commercially available MR
conditional cardiac pacemakers [86,87]. Importantly,
each MR conditional system is composed of an MR con-
ditional pulse generator, MR conditional leads, and MR
conditional programming (Table 2). These and other
manufacturers have systems in development and testing.
Each system has its own individual conditions which
must be adhered to. Therefore, knowledge of the indivi-
dual system conditions is essential for the safe perfor-
mance of MR scanning. In reference to scanner type,
the currently approved field strength is 1.5 Tesla, and
scanning is not approved for field strengths above or
below this strength. Due to rapid advances in technol-
ogy and clinical studies, them e d i c a ls t a f fi n v o l v e di n
this field must continually update their knowledge base
related to MR conditional cardiac devices. This includes
information on changes in devices and MR conditions
as specified by the approving agency in the country
where the device is being implanted and patient
scanned.
Design and Engineering Issues
A cardiac pacemaker system is composed of leads and a
pulse generator composed of connectors, circuitry, and
a battery. In regard to the MRI environment, factors
related to magnetic field interactions and transfer of
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Page 2 of 13Table 1 MRI in Patients with Pacemakers and ICDs
Author Device Year Patient/
Studies Report
Type
MRI
Condition
Findings
Iberer [8] PPM 1987 1/1 Case No adverse effect
Alonga
[11]
PPM 1989 1/1 Case
Intentional
1.5 T
Brain
No adverse effect
Inbar [12] PPM 1993 1/1 Case
Intentional
1.5 T
Brain
No adverse effect
Gimbel
[15]
PPM 1996 5/5
Retrospective
Intentional
0.35-1.5T
Cardiac, Brain,
C-Spine
Two second pause
Garcia-
Boloa [16]
PPM 1998 1/2 Case
Intentional
1.0 T
Brain
No adverse effect
Fontaine
[98]
PPM 1998 1/1 Case
Intentional
1.5 T
Brain, C-Spine
Rapid pacing
Sommer
[143]
PPM 1998 18/18
Prospective
0.5 T
Brain, Cardiac,
Vascular
Asynchronous mode due to activation of the reed switch in all patients
Sommer
[18]
PPM 2000 45/51
Prospective
0.5 T
Multiple
No adverse effect
Valhaus
[20]
PPM 2001 32/34
Prospective
0.5T
Multiple
Decrease in battery voltage recovered at 3 months
Martin [29] PPM 2004 54/62
Prospective
1.5 T
Multiple
Significant change in pacing threshold in 9.4% of leads, and 1.9% of leads
requiring an increase in programmed output.
Del Ojo
[32]
PPM 2005 13/13
Prospective
2.0 T
Multiple
No adverse effect.
Rozner
[41]
PPM 2005 2/2 Case
Intentional
1.5 T
Thorax,
Lumbar
Transient change to ERI in 1 patient.
Gimbel
[33]
PPM 2005 10/11
Prospective
1.5 T
Brain
C-Spine
Small variances in pacing threshold were seen in four patients.
Sommer
[50]
PPM 2006 115/82
Prospective
1.5 T
Extra-thoracic
Significant increase in pacing threshold, decreased lead impedance, and
decrease in battery voltage. No inhibition of pacing or arrhythmias and no
leads which required an increase in pacing output.
Heatlie
[52]
PPM 2007 5/6 Prospective 0.5 T Cardiac Pacing at maximum voltage at a fixed rate of 100 beats/minute in one
patient.
Anfinsen
[22]
ICD 2002 1/1 Case
Inadvertent
0.5 T
Brain
Inappropriate sensing, battery voltage transient change to EOL.
Fiek [28] ICD 2004 1/1 Case
Inadvert
0.5 T
Brain
Unable to communicate with device.
Coman
[30]
ICD 2004 11/11
Prospective
1.5 T
Cardiac,
Vascular,
General
Brief asymptomatic pause in 1 patient.
Unable to communicate with device in 1 patient.
Gimbel
[34]
ICD 2005 7/8 Prospective 1.5 T
Brain, L-Spine
“Power on reset” electrical reset requiring reprogramming in 1 patient.
Roguin
[39]
ICD 2005 1/1 Case
Intentional
1.5 T Cardiac No adverse effect.
Wollmann
[44]
ICD 2005 1/3 Case
Intentional
1.5 T
Brain
No adverse effect.
Naehle
[46]
ICD 2006 1/1 Case
Intentional
1.5 T
Brain
No adverse effect.
Nazarian
[47]
PPM 31
ICD 24
2006 68/55
Prospective
1.5 T No adverse effect.
Nemec
[48]
ICD 2006 1/1 Case
Unintentional
Not specified
Brain
Noise detected as ventricular tachycardia and ventricular fibrillation, with no
therapy presumably due to magnetic mode activation. Asynchronous pacing
due to noise-reversal mode.
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the specific design of these components.
Pacemaker Design and Magnetic Force Issues
The presence of ferromagnetic content in the strong sta-
tic and gradient magnetic fields of the MR system can
lead to movement and vibration of the cardiac device.
These forces are directly related to the amount and
shape of the ferromagnetic content, the location of this
content in relation to the MR system, and the strength
of the static magnetic field [88]. Although excessive
magnetic field interactions can theoretically cause device
movement, prospective data on both “standard” and MR
conditional pacemakers at 1.5 Tesla did not demonstrate
significant clinical effects [32,57,81].
One pacemaker design mechanism to limit magnetic
field interactions is minimization of ferromagnetic con-
tent of the generator. Reduction of ferromagnetic
Table 1 MRI in Patients with Pacemakers and ICDs (Continued)
Sardanelli
[144]
PPM 2006 1/1 Case
Intentional
1.5 T
Breast
No adverse effect.
Mollerus
[56]
PPM 32
ICD 5
2008 37/40
Prospective
1.5 T
Truncal, non-
truncal
No adverse effect.
No changes in cardiac troponin-I
Naehle
[57]
PPM 2008 44/51
Prospective
3.0 T
Brain
No adverse effect.
No changes in cardiac troponin-I
(Use of transmit-receive head coil)
Gimbel
[59]
PPM 2009 1/1 Case
Intentional
2.0 T
Brain
Asystole
Goldsher
[60]
PPM 2009 1/1 Case
Intentional
1.5 T
Cervical
No adverse effect.
Scan one day after implant
Pacemaker dependent
Mollerus
[61]
PPM 46
ICD 6
2009 52/59
Prospective
1.5 Truncal,
non-truncal
MRI-related ectopy 7 pt
Naehle
[62]
PPM 2009 47/171 Case
Intentional
1.5 T
General
Statistically significant but clinically irrelevant change in pacing capture
threshold and battery voltage.
2 or more serial scans.
Pulver [64] PPM 2009 8/11
Prospective
1.5 T
Cardiac, non-
cardiac
No adverse effect.
Congenital heart disease with 9 epicardial leads.
Strach [67] PPM 2010 114/114
Prospective
0.2 T
General
No adverse effect
Millar [66] PPM 2010 1/1 1.5 T
Brain C-spine
No adverse effects
Burke
[117]
PPM 24
ICD 10
CRT ICD 4
2010 38/92
Prospective
1.5 T
Brain, Spine,
Pelvis,
Extremity
No adverse effects
No changes defibrillation threshold (ICD)
Buendia
[100]
PPM 28
ICD 5
2010 33/33
Prospective
1.5 T
Cardiac Brain,
Spine,
Abdominal,
Extremity
Temporary communication failure in two patients.
Sensing errors during imaging in two patients.,
Safety signal generated in one pacemaker at the maximum magnetic
resonance frequency and output level.
Cohen
[70]
PPM 74
ICD 31
2010 105/105
Prospective
1.5 T No deaths, device failures, genrerator/lead replacements, loss of capture, or
electrical reset.
Decrease in battery voltage of ≥ 0.04 V in 2%
Lead impedance change ≥ 50 Ohms in 3%
High voltage impedance change ≥ 3 Ohms in 10%
Decrease in R wave amplitude in 2%
Pacing threshold increase of ≥ 0.5 V at 0.4 ms in 1% of leads
Wilkoff
[81]
MR
ConditionalPPM
2011 226/226
Prospective
1.5 T
Brain and
lumbar
No adverse effect
Quarta
[140]
MR
ConditionalPPM
2011 1/1 Prospective 1.5 T
Brain, Cardiac
No adverse effect
Adapted and Updated from Shinbane et al. 2007. [1]
Case = case report, EOL = end-of-life, ERI = elective-replacement indices; ICD-implantable cardiac defibrillator; PPM = pacemaker; T = Tesla,.
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netic conductive substances in the pacemaker generator.
The leads are made of nonmagnetic materials. There are
significant limitations on t h ec h o i c eo fn o n - f e r r o m a g -
netic materials, as the materials must be appropriately
conductive, durable, and biocompatible.
An MRI-related factor which can decrease magnetic
field interactions is the use of a lower magnetic field
strength. Another factor is the maximization of the dis-
tance between the cardiac device and scanner during
imaging. An example of this is a dedicated extremity
MR system to scan the patient [17]. The further
Table 2 MRI Patient and Scanner Conditions for Clinically Released MR Conditional Systems in the United States or
the European Community
System Medtronic EnRhythm MRI™
SureScan™ Pacing System
St. Jude Medical™ MR Conditional
Pacing System
Biotronik ProMRI™ MR Conditional
Pacing System
Approval United State (FDA appoval)
European Community (CE approval)
European Community (CE approval) European Community (CE approval)
Studies Wilcoff et al. [81]
Forleo et al. [82]
Advisa MRI Study [83]. (In process)
Accent MRI Study [145]. (In process)
Implant site Left or right pectoral region Left or right pectoral region Chest area.
Patient’s height at least 1.4 meters
Limitations
related to other
devices/leads
No active or abandoned medical devices,
leads, lead extenders or adaptors
No abandoned cardiac hardware
including leads, lead extenders, or lead
adaptors
No other pacemakers or ICDs, leads no
longer in use, lead adapters, lead
extension
Implant timing
prior to MRI
At least six weeks Stable pacing capture threshold values At least 6 weeks.
Acceptable lead
parameters for
MRI
Capture thresholds of ≤ 2.0 V at a pulse
width of 0.4 ms
Impedance of ≥ 200 and ≤ 1500 Ohms
No diaphragmatic pacing at 5.0 V at a
pulse width of 1.0 ms
Capture threshold values of ≤ 2.5 V at 0.5.
ms pulse width
Lead impedance measurements within
the programmed lead impedance limits
No diaphragmatic stimulation at a pacing
output of 5.0 V or 7.5 V and at a pulse
width of 1.0 ms if device will be
programmed to an asynchronous pacing
mode when MRI Settings are enabled
Capture threshold ≤ 2.0 V at 0.4 ms pulse
width
Lead impedance is between 200 and
1500 Ohms ￿
Battery charging status: at least 30%
Programming
for MRI
MR conditional programming modes MR conditional programming modes MR conditional programming modes
Device
Identifiers
Pulse generator radiopaque marking with
a unique symbol and three letter code
Unique radiopaque lead helix design
A radio-opaque MRI symbol is present on
all implanted St. Jude Medical™ MR
Conditional pacing system components
Radiopaque MR Conditional lead marker
Pulse generator radiopaque marking.
No lead radiopaque identifier
Scanner 1.5 Tesla cylindrical bore MR system 1.5 Tesla horizontal closed bore MR
system
1.5 Tesla cylindrical bore MR system
Landmark
isocenter of RF
coil
United States: Superior to C1 or inferior to
T12
Ensura MRI™ SureScan™ Pacing System
and Advisa DR MRI™ SureScan™
pacemaker labeling has no restrictions on
chest scans outside the United States
Contraindication to use of local transmit-
only coils or local transmit and receive
coils placed directly over the pacing
system
Maximum allowed positioning mark for
the isocenter starting from the foot at
the hip bone level. and maximum
allowed positioning mark for the
isocenter from the top of the skull at the
level of the eyes).
Patient
Positioning
Contraindication to lateral decubitus
patient positioning
Must not be positioned on side Dorsal position only.
Scanner Mode Scanner in’ the normal operating mode
(defined as the mode of operation of the
MR system in which none of the outputs
have a value that cause physiological
stress to patients)
Scanner in the normal operating mode or
First Level Controlled operating mode
The overall MR scanning time
accumulated from the imaging times as
displayed by the MRI scanner must not
exceed 30 minutes
The total accumulated length of
examination for the pacing system must
be below 10 hours
Radiofrequency
Energy
Maximum gradient slew rate ≤ 200 T/m/s
per axis
Whole body specific absorption rate (SAR)
levels ≤ 2 W/kg
Head SAR ≤ 3.2 W/kg
Maximum gradient slew rate ≤ 200 T/m/s
per axis
Whole body specific absorption rate (SAR)
≤ 4.0 W/kg
Head SAR ≤ 3.2 W/kg
Maximum gradient slew rate ≤ 200 T/m/s
per axis
Whole body specific absorption rate
(SAR) ≤ 2.0 W/kg
Head SAR ≤ 3.2 W/kg
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factors may be useful [17,89,90].
An additional magnetic field interaction is related to
the effect of a static magnetic field of the MR system on
the pacemaker reed switch. The reed switch is a feature
in many pacemakers designed to program a pacemaker
by means of a magnet placed over the device. Reed
switch magnet responses in pacemakers may cause
changes to a continuous asynchronous pacing mode
(DOO or VOO) in order to avoid electromagnetic inter-
actions during such procedures as surgery with the use
of electrocautery (i.e., which generates electromagnetic
interference) [91]. Reed switch activation associated with
exposure to an MR system may not be predictable. It
may vary with strength of the static magnetic field and
with orientation of the reed switch to the magnetic field
[14,26,36]. Given this unpredictability, an MR condi-
tional pacemaker has been designed with replacement of
the reed switch with a solid state Hall sensor [80,81].
The Hall sensor has a more predictable behavior when
exposed to magnetic fields. Another pacemaker has a
magnet detect sensor that prevents problems with the
reed switch [92]. Future design related to magnetic field
will need to also address higher field strengths
[57,59,93].
Pacemaker Design and Electromagnetic Energy
Conduction Issues
Electromagnetic energy from the MR scanner can con-
duct through the pacing system or cause electrical inter-
ference with components of the system. Sources of this
electromagnetic energy include the pulsed radiofre-
quency energy from a head or body coil and the time
varying magnetic fields used by the MR system for spa-
tial localization of signals. The transfer of radiofre-
quency energy to heat and electrical energy is
dependent on factors including: 1) the pulse sequence
parameters, 2) the whole body averaged and local speci-
fic absorption rates (SAR) associated with a given
sequence, 3) spatial relation and orientation of the anat-
omy to the transmit RF coil, and 4) lead factors (compo-
sition, length, geometry, configuration, and orientation)
[51,54,55,63,94-97].
Pacing leads can potentially act as antennae for elec-
tromagnetic energy impulses [27,98]. The transfer of
electromagnetic energy can lead to myocardial electrical
stimulation, tissue destruction at the lead tip/endocar-
dial interface, pain, and damage to the pulse generator
circuitry/battery. This may produce adverse effects on
sensing, pacing thresholds, and lead impedances, and
can cause inappropriate pacing acceleration or inhibi-
tion, and battery depletion [4,6,7,9,20,29,31,33,
36,41,43,50,52,61,62,98-100] In a recent investigation by
Wilkoff et al. [81] on an MR conditional pacing system,
these adverse effects were not observed. Pacing thresh-
olds did not change significantly between patients with
the device who were scanned and those who served as
control patients.
Factors involved in pacemaker lead design relate to
avoidance of the resonant frequency as well as the lead
length, configuration, and position. As a lead can act as
a receiver of electromagnetic impulses, avoiding the
resonant frequency of a lead is of extreme importance.
A resonant lead length has been associated with a
greater heating effect [101].
A pacemaker lead is composed of an outer and inner
insulation and an outer and inner lead coil. The lead
coil is arranged in a configuration to maximize energy
efficient conduction while maintaining flexibility, dur-
ability and minimization of lead diameter. The inner
coil is made of filaments wound in a three-dimensional
relationship coiled with a certain pitch. This has impli-
cations for MRI-related energy conduction based on the
resonant frequency of the lead [35].
An example of lead design changes in an MR condi-
tional lead is a lead modification due to a change in the
pitch of the inner coil [102]. The inner coil was
designed with a decreased number of coiled filars,
increasing the number of winding turns and, therefore,
increasing the lead inductance. This geometry limits the
radiofrequencies that can conduct through the lead fila-
ments. The decrease in the number of filars required an
increase in the filar diameter to increase the strength of
the lead. Additionally, a lead tip coating was used with a
substance that decreased polarization. As unipolar
pacing is more susceptible to the MRI environment, a
bipolar lead design was used so that the generator was
not essential to the pacing circuit [21,43].
Measurements of lead heating with in vitro models
can be challenging [103]. In models, many factors affect
heating at the lead tip including length and the geo-
metric structure of the lead, phantom shape, and posi-
tion of the radiofrequency coil. Closer proximity of
leads to the edge of the phantom and to the edge of the
coil caused greatest heating [55]. Another phantom
study at 1.5 T demonstrated greatest heating with the
torso centered along the superior-inferior direction of
the transmit coil [97]. In vitro study of lead design has
demonstrated increased heating with increased lead
insulation thickness and uncoiled leads of 25-50 cm
length [104]. This study demonstrated decreased heating
with increased lead impedance and winding configura-
tion with reversed winding segments.
Abandoned leads can also conduct radiofrequency
energy. In an in vivo study of clinical lead lengths (40-
60 cm), abandoned leads demonstrated greater lead tip
heating in comparison to leads attached to pulse genera-
tors [68]. Therefore, no additional abandoned leads
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abandoned leads, special attention to the patient’s device
history regarding abandoned leads is important.
Circuitry filters to impede or limit the transfer of cer-
tain frequencies, circuits that divert and dissipate energy,
and generator shielding can also be important to design
in order to avoid or minimize the transfer of electro-
magnetic energy. Of note, retained epicardial wires cut
short at the skin level from previous cardiothoracic sur-
gery procedures do not appear to be associated with ser-
ious MRI-related issues [105,106].
Application of Defined MR Conditions
Of paramount importance to the implementation of
these new technologies is the education and training of
the medical community involved in care of cardiac
device patients who are undergoing MR scans. The
goals of education are to provide optimal patient care
and efficient patient flow in the MR center. This
includes understanding of the pacemaker programming
to an MR conditional mode. The design of the program-
ming hardware and software must include features to
inactivate sensing, internal assessment of system integ-
rity, and clear programming return to pre-scan values.
The decision as to the appropriate pacing mode during
MR scanning requires arrhythmia expertise. Understand-
ing of the patient’s initial indication for the device,
arrhythmia history, and underlying rhythm/pacemaker
dependence are important aspects of clinical information.
The underlying sinus rate, AV nodal conduction, and
presence rate and location of escape rhythms are impor-
tant in making decisions as to the appropriate program-
ming mode (Figure 1). Additionally, many pacemakers
have logs listing the percentage of time that a patient is
paced in the atrium or ventricle. One needs to interpret
this data though in regard to the programmed pacing
r a t ea n dp r o g r a m m e dA Vi n t e r v a l s ,a st h ep a t i e n tm a y
have a regular rhythm under these programmed para-
meters. As predicting bradyarrhythmic or tachyarrhyth-
mic events on a beat by beat basis is challenging, even
when the appropriate mode is chosen based on past his-
tory, meticulous and continuous monitoring of the
patient’s heart rate and rhythm is required while the
patient is programmed in the appropriate MR conditional
mode. Asynchronous pacing is used with scanning a
pacemaker dependent patient. In those patients with an
underlying rhythm who are not bradycardic, a ventricular
rate competing with the asynchronous pacing could lead
to pacing during ventricular repolarization, potentially
causing an R on T phenomenon leading to life threaten-
ing ventricular arrhythmias [36,107,108].
The pacemaker programmer device must be outside
of the MR scanner room. Device programming imme-
diately before entering the MRI environment and
device interrogation and reprogramming immediately
after removal from the MRI environment can limit the
amount of time that the patient is in the MR condi-
tional mode. Before MRI scanning, the initial program-
ming mode is stored, so that devices can be
programmed back to the original settings.
Figure 1 Intracardiac Electrocardiograms Demonstrating Pacemaker Dependence. Upper Panel: The presenting rhythm is sinus rhythm at
80 beats per minute with ventricular pacing. Middle Panel: Asynchronous dual chamber pacing. Lower Panel: The underlying rhythm is sinus
with complete heart block with ventricular pacing at 35 beats per minute. This patient has complete heart block with no ventricular escape at
35 beats per minute.
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monitoring equipment, the MRI environment causes
artifacts in the recordings. Therefore, meticulous atten-
tion to ECG electrode pad positioning and skin prep
must be performed to assure adequate monitoring
[109,110]. Visual and verbal assessment of the patient’s
level of consciousness, blood pressure and pulse oxime-
try monitoring provide additional mechanisms to alert
the MRI technologists, nurses, and/or physician of any
unusual sensations or issues. The presence of healthcare
professionals who have completed training in the pro-
gramming and scanning of the specific MR conditional
device and availability of a defibrillator (albeit, to be
used outside of the MR system room), are essential.
Although scanning a patient with an MR conditional
device following the strict patient and MRI-related con-
ditions appears straightforward, issues that impact
patients with pre-existing devices remain complex. Until
MR conditional devices are the routine platform for all
of these devices, there will still be challenging decisions
regarding using MRI in patients with pre-existing
devices where imaging is required to diagnose and man-
age a potentially life threatening scenario, such as a cen-
tral nervous system tumor, cord compression, stroke or
h e m o r r h a g e[ 4 4 , 4 7 , 6 0 ] .T h ep r e v i o u sd a t a b a s ef o rn o n -
MR conditional devices is, therefore, still important in
individualizing the risk:benefit ratio in these challenging
circumstances [1,69,111,112].
As the MR conditional system was designed for the
pulse generator to be used only with the MR conditional
leads, an MR conditional generator cannot be simply
attached to pre-existing leads and retain MR conditional
labeling. A decision would need to be made as to
whether to scan the patient with their pre-existing sys-
tem or whether to extract the pacing system and place
an MR conditional cardiac pacemaker. Because there
can be significant complications with system extraction
and replacement, including vascular damage, cardiac
perforation, infection, etc., the risk:benefit ratio of these
options needs to be carefully decided by physicians with
expertise in these areas [113]. Additional questions will
relate to the best approach to generator change-outs in
patients at elective replacement who will likely require
MRI procedures in the future, recognizing that change
to a MR conditional system requires explant of the
entire system including leads and implant of new
system.
Special Design Issues Related to ICDs
Data related to the use of MRI in patients with ICDs are
limited with variable results, with some isolated reports
demonstrating no significant effects while others
described issues with ability to communicate with the
ICD post scan, sensing of electromagnetic noise, and
changes in battery voltage [22,28,34,39,44,46-48,
53,56,61,88,100]. ICDs possess additional complexity
compared to pacemakers due to the larger size and
complexity of leads, circuitry related to arrhythmia
detection and treatment, and capacitors for cardiover-
sion and defibrillation [114-116].
The increased ferromagnetic content of ICDs com-
pared to pacemakers will require special attention to
design and study of magnetic field interaction issues.
Magnetic field interactions with the magnet response of
many ICDs may cause inactivation of arrhythmia detec-
tion leading to inhibition of ICD therapies. Reliable
magnetic responses in the MRI environment will need
to be assessed as well as programming to ensure that
ICD antitachycardia pacing, cardioversion and defibrilla-
tion therapies are not attempted by the ICD while the
patient is in the MR scanner.
With ICDs, transmitted electromagnetic currents asso-
ciated with MRI could potentially trigger tachyarrhyth-
mia detection, if detection is not programmed to the
“off” mode before MRI. It is unclear, though, whether
ICD capacitors can charge in the presence of the MR
system’s powerful static magnetic field [46]. ICD pro-
gramming in the MRI environment will require reliable
and clear mechanisms to deactivate sensing modes to
avoid inappropriate sensing of radiofrequency energy, as
well as programming of pacing modes along the lines of
MR conditional pacemakers.
Special intra-scan issues related to ICDs stem from
the fact that these patients typically have an underlying
cardiac substrate predisposing them to potentially life
threatening ventricular arrhythmias. The arrhythmia his-
tory regarding the frequency of arrhythmias and overall
cardiovascular patient stability are important, and these
patients require meticulous monitoring while therapies
are inactivated during an MRI examination. Program-
ming design will also need to provide straight forward
mechanisms to activate and confirm the original pro-
gramming post-scan. The need for post-scanning ICD
defibrillation threshold testing is another issue which
warrants further assessment [117].
Future Issues Related to the Spectrum of Cardiac Devices
and Scanners
Given the expanding role of biomedical devices in diag-
nosis and treatment of medical conditions, design and
engineering will play an important role in the future of
many technologies as they relate to the MRI environ-
ment [118]. The gamut of cardiac devices includes
atrial/biventricular and biventricular pacemakers and
ICDs, subcutaneous ICDs, arrhythmia monitors and
implantable physiologic measurement devices, and tem-
porary pacing systems. Each of these technologies has a
different lead number, shape, size and location, as well
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neuromodulation devices (including those devices used
for vagus nerve stimulation, deep brain stimulation,
spinal cord stimulation, and stimulation of other organs)
derived from cardiac pacemaker technologies are being
implanted in patients with potential problematic MRI
interactions and, thus, the need for further design modi-
fications [119-125].
MRI is also utilized to direct such procedures as car-
diac vascular/valvular interventions, cardiac electrophy-
siology procedures, biopsy, surgical, ablative, cryogenic,
directed chemotherapeutic procedures, and neuromodu-
lation treatments [126-137]. Biomedical device design
changes will be necessary to allow the use of these tech-
nologies when they are MR-guided to avoid device/ima-
ging interactions [138,139].
Design and engineering will not only need to take
into account safety, but also: 1) the effect of MR con-
ditional devices on diagnostic quality of the MR
images, 2) application to cardiac imaging, 3) cost effec-
tiveness and 4) impact on overall patient care. As MRI
artifacts principally affect the local region of implanted
devices, for pacemakers, ICDS, and other cardiac bio-
medical devices, artifact issues will be most important
to cardiovascular and thoracic imaging [31,39,64,140].
The currently released MR conditional pacemaker in
the United States requires specific landmarking steps
be taken to acquire cardiac images, although not in
Europe. In the European Community, the Biotronik
system has a scan exclusion zone with the maximum
allowed positioning mark for the isocenter starting
from the foot at the hip bone level and the maximum
allowed positioning mark f o rt h ei s o c e n t e rf r o mt h e
top of the skull at the level of the eyes, while the St.
Jude system specifies contraindication only to the
transmit-only or local transmit and receive coils
directly over the pacing system [81,86,87].
Both isocenter and artifact issues are important to the
future of cardiac imaging using MR conditional pace-
makers. Regarding artifacts from the pacer components,
there is no easy solution, as gradient echo and steady
state free precession images may be significantly dis-
torted by regional changes in magnetic field homogene-
ity. For MRI examinations involving the region of the
thorax, issues related to artifacts (i.e., both signal loss
and image distortion) will obviously have great impor-
tance. In one study of patients with cardiac pacemakers
or ICDs, 93% of thoracic scans were diagnostically
acceptable [47].
Regarding chest imaging, issues of stress testing neces-
sitate further investigation. The underlying lack of
chronotropic competence in many patients with pace-
makers and well as current programming algorithms
with fixed pacing rates or programmed off for MR con-
ditional pacemakers could be challenging for studies
which require an elevation to 85% of the maximum of
heart rate with stress. Coronary vasodilator stress would
appear to be the most practical approach, but require
further study. As with many new technologies, decisions
regarding implementation in populations, cost, reimbur-
sement and continued future design systems will need
to be investigated (Table 3).
Conclusions
The advancement of MR conditional technology has led
to greater options for patient management and has also
resulted in greater complexity of clinical issues. The cur-
rent MR conditional pacing technology provides definite
solutions to some specific issues related to MR scan-
ning. Future design, engineering, testing, and
Table 3 Issues Raised by the Advent of MR Conditional Cardiac Devices Which Require Further Study.
Patient Selection Who should receive MR conditional devices?
Should MR conditional devices become the standard platform or used only in those patients with a higher risk of needing
MR scanning in the future?
Who is at highest risk of needing future MR scanning?
Medical
Coordination
What are the most efficient and safest algorithms for coordination of medical staff from multiple disciplines (radiology,
cardiology, cardiac electrophysiology, pacemaker technicians, MR technicians), in assessing, monitoring, and scanning
patients?
Study Type and
Quality
What is the spectrum of MR studies that can be performed with MR conditional cardiac devices regarding study types,
imaging sequences, and the use of stress testing?
What is the impact of MR conditional devices on image quality?
How can cardiac MR imaging be performed with MR conditional devices?
Impact on Care Does use of MR conditional cardiac devices improve the quality of patient care?
What is the optimal approach to MR scanning in a patient with a non-MR conditional device in place regarding risks of
extraction and replacement versus scanning with the implanted system?
Cost What is the impact of implantation of MR conditional devices on device cost, physician and technologist time and cost for
assessment and monitoring of patients?
How should reimbursement and reimbursement codes for system placement and peri-scanning monitoring/device
assessment be determined?
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of broadening these applications to further decreasing
the barriers to scanning patients with cardiac and non-
cardiac, electronically-activated devices. Although the
current literature provides data on the first generation
of MR conditional cardiac pacemakers from multi-cen-
ter trials conducted at research centers, post market
data will be essential to assess impact of implementation
of this technology in “real world” scenarios and provide
long term data on the function of these systems
[102,141]. The impact of MR conditional pacemakers
will also be dependent on implant rates of pacemakers
versus ICDs, which vary by country [142]. Further
research is required on multiple issues related to MRI
interactions with devices, including, the effects of multi-
ple scans on these systems and system effects at higher
static magnetic field strengths [102]. The design, devel-
opment, study and implementation of cardiovascular
MR conditional devices will continue to require the
expertise and collaboration of multiple disciplines and
will need to prove safety, effectiveness and cost effec-
tiveness in patient care.
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